Drug Target Review

APRIL 7, 2025

GPCRs are critical targets for drug development due to their involvement in numerous disease pathologies, with many medications working by either activating or inhibiting these receptors. 2 Considering 2530 percent of marketed drugs work by binding to GPCRs, 3 it is vital that these challenges are overcome through innovation and research.

Fragment Screening 52

Fragment Screening Drugs Biophysical Assays Small Molecule 52

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96

RNA Small Molecule Disease Assay Development 96

Broad Institute

JUNE 30, 2023

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. The researchers also looked at the tool’s ability to detect changes in cellular phenotypes after exposure to drugs and small molecule compounds.

Small Molecule 106

Small Molecule Cell Based Assays Disease Assay Development 106

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. Acta Cryst. Acta Cryst. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

PPD

OCTOBER 18, 2023

With the depth of knowledge to support all types of pharmaceutical products across all phases of development, we provide services ranging from end-to-end assay development to platform expansion, designed with the client’s timeline and budget in mind. Stay ahead of the curve with a great GMP/CMC contract laboratory partner.

Laboratories 52

Laboratories Assay Development Small Molecule Drug Development 52

Sygnature Discovery

SEPTEMBER 14, 2023

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. The biotech’s aim is to develop medicines that treat the underlying cause of heart failure rather than merely treating the symptoms.

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52

Elrig

APRIL 29, 2024

Miguel Gancedo Rodrigo Miguel Gancedo Rodrigo Research Investigator, Isomorphic Labs My name is Miguel, and I’m from Murcia, Spain. Rising from Research Scientist to Senior Scientist, I supported early-stage DD efforts within their Protein Science group, based in Cambridge, UK.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59